Health Technology

AnGes, Inc.

Business Summary

AnGes, Inc. engages in the research and development of gene-based medical products. It offers genetic medicines such as hepatocyte growth factor (HGF) genetic medicines, NF-KB decoy oligo and hemagglutinating virus of Japan envelope (HVJ-E) non-viral vector, and others. It is also involved in the research and development of medical equipment, which improves blood circulation by regenerating blood vessels and NfkB which controls various inflammations. The company was founded on December 17, 1999 and is headquartered in Ibaraki, Japan.

Financial Highlights

Dec 2022	JPY	USD
Revenue	67.06M	0.50M
Gross Profit	-2,920.27M	-22.20M
Operating income	-16,316.80M	-124.05M
Income before tax	-14,716.99M	-111.89M
Net income	-14,714.77M	-111.87M
EBITDA	-13,414.97M	-101.99M
Diluted EPS	-94.29	-0.71
Dividends Per Share	0	0
Total Assets	38,820.71M	294.21M
Total liabilities	8,395.30M	63.62M
Total equity	30,425.40M	230.59M
Operating cash flow	-11,214.24M	-85.26M
	Currency in JPY	Currency in USD

Historical Data

JPY | USD

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022
Revenue	610.05M	326.75M	39.99M	64.14M	67.06M
Gross Profit	418.87M	235.16M	12.06M	-2,410.09M	-2,920.27M
Operating income	-3,065.25M	-3,270.00M	-5,599.39M	-15,632.08M	-16,316.80M
Income before tax	-3,003.00M	-3,751.60M	-4,204.95M	-13,735.29M	-14,716.99M
Net income	-2,996.62M	-3,750.82M	-4,209.51M	-13,675.58M	-14,714.77M
EBITDA	-3,057.39M	-3,262.68M	-5,591.80M	-13,206.00M	-13,414.97M
Diluted EPS	-34.46	-35.81	-35.32	-92.85	-94.29
Dividends Per Share	0	0	0	0	0
Total Assets	8,050.67M	12,524.60M	38,354.61M	45,455.74M	38,820.71M
Total liabilities	316.21M	469.24M	5,674.93M	6,821.00M	8,395.30M
Total equity	7,734.45M	12,055.35M	32,679.67M	38,634.74M	30,425.40M
Operating cash flow	-2,522.50M	-2,179.91M	-2,961.32M	-11,380.54M	-11,214.24M

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022
Revenue	5.52M	2.99M	0.37M	0.58M	0.50M
Gross Profit	3.79M	2.15M	0.11M	-21.93M	-22.20M
Operating income	-27.75M	-29.99M	-52.44M	-142.27M	-124.05M
Income before tax	-27.19M	-34.41M	-39.38M	-125.01M	-111.89M
Net income	-27.13M	-34.40M	-39.42M	-124.46M	-111.87M
EBITDA	-27.68M	-29.92M	-52.37M	-120.19M	-101.99M
Diluted EPS	-0.31	-0.32	-0.33	-0.84	-0.71
Dividends Per Share	0	0	0	0	0
Total Assets	73.37M	115.24M	371.49M	394.73M	294.21M
Total liabilities	2.88M	4.31M	54.96M	59.23M	63.62M
Total equity	70.49M	110.93M	316.52M	335.50M	230.59M
Operating cash flow	-22.83M	-19.99M	-27.73M	-103.57M	-85.26M

Valuation Measures

Dec 2022
PER	--
ROA	-34.92%
ROE	-42.61%
Operating margin	-24,331.28%
Profit margin	-21,942.36%

Management

President & Representative Director: Ei Yamada
Director, Executive Officer & Manager-Finance: Tetsuji Yoneo
Director & Manager-Drug Discovery Research: Kazuo Suzuki
Executive Officer, Manager-R&D Promotion: Hajime Watanabe
Manager-Accounting: Jun Sakurai

Shareholders

HAYASHI YUICHIRO (0.6%)
Shionogi & Co., Ltd. (0.6%)
KAWAI HIROSHI /SAKAI/ (0.5%)
MORISHITA RYUICHI (0.3%)
OTSUKI TOSHIMI (0.3%)
Dimensional Fund Advisors LP (0.1%)
Siemens Fonds Invest GmbH (0.0%)
SSgA Funds Management, Inc. (0.0%)
SPARX Asset Management Co., Ltd. (0.0%)
Dimensional Fund Advisors Ltd. (0.0%)

Contact Details

Website:http://www.anges.co.jp
Address: Saito Bio-Incubator, 1/F, 7-7-15 Saito-Asagi, Osaka, 567-0085, Japan
Phone: +81.72.643.3590

Related Companies

Emendo Biotherapeutics, Inc.
AnGes USA, Inc.
AnGes Euro Ltd.

Competitors

Athira Pharma, Inc.
Editas Medicine, Inc.
Sienna Biopharmaceuticals, Inc.

Last Updated on 22 Sep, 2023